Ieq Capital LLC Invests $969,000 in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Ieq Capital LLC acquired 43,625 shares of Kiniksa Pharmaceuticals, valued around $969,000, representing roughly 0.06% ownership as of the last quarter.
• Insider activity included significant sales by CAO Michael R. Megna and CFO Mark Ragosa, decreasing their holdings by 33.97% and 41.15% respectively, with a total of 532,312 shares sold by insiders in the past 90 days.
• Kiniksa's stock reported a market cap of $2.54 billion and a quarterly EPS of $0.23, exceeding estimates, with analysts giving it a consensus "Buy" rating and an average target price of $41.17.

Ieq Capital LLC purchased a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 43,625 shares of the company's stock, valued at approximately $969,000. Ieq Capital LLC owned 0.06% of Kiniksa Pharmaceuticals International at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. US Bancorp DE purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $33,000. Asset Management One Co. Ltd. purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $41,000. Wealthquest Corp purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $42,000. Finally, Lazard Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $61,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Stock Up 0.6%

Shares of NASDAQ KNSA traded up $0.20 during trading hours on Friday, hitting $35.71. 328,234 shares of the stock were exchanged, compared to its average volume of 429,216. The company has a market cap of $2.65 billion, a PE ratio of 892.97 and a beta of 0.20. The firm has a fifty day moving average price of $30.95 and a 200-day moving average price of $26.54. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $35.84.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. The firm had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 17,000 shares of the company's stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $32.35, for a total transaction of $549,950.00. Following the transaction, the chief accounting officer owned 33,041 shares in the company, valued at approximately $1,068,876.35. This represents a 33.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Thomas Malley sold 78,233 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the transaction, the director owned 12,546 shares in the company, valued at $415,147.14. The trade was a 86.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 558,403 shares of company stock worth $18,078,671 in the last three months. 53.48% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have issued reports on KNSA. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Finally, Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.